These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26416286)

  • 1. A streamlined search technology for identification of synergistic drug combinations.
    Weiss A; Berndsen RH; Ding X; Ho CM; Dyson PJ; van den Bergh H; Griffioen AW; Nowak-Sliwinska P
    Sci Rep; 2015 Sep; 5():14508. PubMed ID: 26416286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma.
    Rausch M; Weiss A; Achkhanian J; Rotari A; Nowak-Sliwinska P
    Br J Cancer; 2020 Aug; 123(4):556-567. PubMed ID: 32439932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib.
    Luo H; Quan J; Xiao H; Luo J; Zhang Q; Pi G; Ye Y; He R; Liu Y; Su X; Zhao L; Wang G
    Oncol Rep; 2018 May; 39(5):2270-2278. PubMed ID: 29517107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Synergistic anti-tumor effects of axitinib and doxorubicin].
    Xu XL; Huang Y
    Yao Xue Xue Bao; 2016 Aug; 51(8):1250-6. PubMed ID: 29897727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
    Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
    Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells.
    Veschi S; De Lellis L; Florio R; Lanuti P; Massucci A; Tinari N; De Tursi M; di Sebastiano P; Marchisio M; Natoli C; Cama A
    J Exp Clin Cancer Res; 2018 Sep; 37(1):236. PubMed ID: 30241558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner.
    Morelli MB; Amantini C; Nabissi M; Cardinali C; Santoni M; Bernardini G; Santoni A; Santoni G
    Oncotarget; 2017 Jan; 8(2):3380-3395. PubMed ID: 27926485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
    Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
    PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
    Miyazaki A; Miyake H; Fujisawa M
    Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
    Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
    Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of drug combinations using Feedback System Control.
    Nowak-Sliwinska P; Weiss A; Ding X; Dyson PJ; van den Bergh H; Griffioen AW; Ho CM
    Nat Protoc; 2016 Feb; 11(2):302-15. PubMed ID: 26766116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
    Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):329-40. PubMed ID: 23736154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of ruthenium(II)-arene complex [Ru(η
    Berndsen RH; Weiss A; Abdul UK; Wong TJ; Meraldi P; Griffioen AW; Dyson PJ; Nowak-Sliwinska P
    Sci Rep; 2017 Feb; 7():43005. PubMed ID: 28223694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.
    Haltia UM; Andersson N; Yadav B; Färkkilä A; Kulesskiy E; Kankainen M; Tang J; Bützow R; Riska A; Leminen A; Heikinheimo M; Kallioniemi O; Unkila-Kallio L; Wennerberg K; Aittokallio T; Anttonen M
    Gynecol Oncol; 2017 Mar; 144(3):621-630. PubMed ID: 28104295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer.
    Weiss A; Ding X; van Beijnum JR; Wong I; Wong TJ; Berndsen RH; Dormond O; Dallinga M; Shen L; Schlingemann RO; Pili R; Ho CM; Dyson PJ; van den Bergh H; Griffioen AW; Nowak-Sliwinska P
    Angiogenesis; 2015 Jul; 18(3):233-44. PubMed ID: 25824484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.
    Ren S; Rivard CJ; Yu H; Genova C; Rozenboom L; Gao D; Hinz TK; Rikke BA; Wynes MW; Caldwell C; Agustoni F; Kenichi Suda ; Jiang T; Zhou C; Heasley LE; Hirsch FR
    Clin Lung Cancer; 2018 Sep; 19(5):450-456. PubMed ID: 30146263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental design and statistical analysis for three-drug combination studies.
    Fang HB; Chen X; Pei XY; Grant S; Tan M
    Stat Methods Med Res; 2017 Jun; 26(3):1261-1280. PubMed ID: 25744107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.